BACKGROUND:Prescription opioid dependence is a growing problem, but little research exists on its treatment, including patient characteristics that predict treatment outcome. METHODS: A secondary analysis of data from a large multisite, randomized clinical trial, the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study (POATS) was undertaken to examine baseline patient characteristics (N=360) associated with success during 12-week buprenorphine/naloxone treatment for prescription opioid dependence. Baseline predictor variables included self-reported demographic and opioid use history information, diagnoses assessed via the Composite International Diagnostic Interview, and historical opioid use and related information from the Pain And Opiate Analgesic Use History. RESULTS: In bivariate analyses, pre-treatment characteristics associated with successful opioid use outcome included older age, past-year or lifetime diagnosis of major depressive disorder, initially obtaining opioids with a medical prescription to relieve pain, having only used opioids by swallowing or sublingual administration, never having used heroin, using an opioid other than extended-release oxycodone most frequently, and no prior opioid dependence treatment. In multivariate analysis, age, lifetime major depressive disorder, having only used opioids by swallowing or sublingual administration, and receiving no prior opioid dependence treatment remained as significant predictors of successful outcome. CONCLUSIONS: This is the first study to examine characteristics associated with treatment outcome in patients dependent exclusively on prescription opioids. Characteristics associated with successful outcome after 12 weeks of buprenorphine/naloxone treatment include some that have previously been found to predict heroin-dependent patients' response to methadone treatment and some specific to prescription opioid-dependent patients receiving buprenorphine/naloxone.
RCT Entities:
BACKGROUND: Prescription opioid dependence is a growing problem, but little research exists on its treatment, including patient characteristics that predict treatment outcome. METHODS: A secondary analysis of data from a large multisite, randomized clinical trial, the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study (POATS) was undertaken to examine baseline patient characteristics (N=360) associated with success during 12-week buprenorphine/naloxone treatment for prescription opioid dependence. Baseline predictor variables included self-reported demographic and opioid use history information, diagnoses assessed via the Composite International Diagnostic Interview, and historical opioid use and related information from the Pain And Opiate Analgesic Use History. RESULTS: In bivariate analyses, pre-treatment characteristics associated with successful opioid use outcome included older age, past-year or lifetime diagnosis of major depressive disorder, initially obtaining opioids with a medical prescription to relieve pain, having only used opioids by swallowing or sublingual administration, never having used heroin, using an opioid other than extended-release oxycodone most frequently, and no prior opioid dependence treatment. In multivariate analysis, age, lifetime major depressive disorder, having only used opioids by swallowing or sublingual administration, and receiving no prior opioid dependence treatment remained as significant predictors of successful outcome. CONCLUSIONS: This is the first study to examine characteristics associated with treatment outcome in patients dependent exclusively on prescription opioids. Characteristics associated with successful outcome after 12 weeks of buprenorphine/naloxone treatment include some that have previously been found to predict heroin-dependent patients' response to methadone treatment and some specific to prescription opioid-dependent patients receiving buprenorphine/naloxone.
Authors: Roger D Weiss; Jennifer Sharpe Potter; David A Fiellin; Marilyn Byrne; Hilary S Connery; William Dickinson; John Gardin; Margaret L Griffin; Marc N Gourevitch; Deborah L Haller; Albert L Hasson; Zhen Huang; Petra Jacobs; Andrzej S Kosinski; Robert Lindblad; Elinore F McCance-Katz; Scott E Provost; Jeffrey Selzer; Eugene C Somoza; Susan C Sonne; Walter Ling Journal: Arch Gen Psychiatry Date: 2011-11-07
Authors: Keith G Heinzerling; James T McCracken; Aimee-Noelle Swanson; Lara A Ray; Steven J Shoptaw Journal: J Clin Psychopharmacol Date: 2012-02 Impact factor: 3.153
Authors: Roger D Weiss; Jennifer Sharpe Potter; Scott E Provost; Zhen Huang; Petra Jacobs; Albert Hasson; Robert Lindblad; Hilary Smith Connery; Kristi Prather; Walter Ling Journal: Contemp Clin Trials Date: 2010-01-29 Impact factor: 2.226
Authors: Michael Mancino; Geoffrey Curran; Xiaotong Han; Elise Allee; Keith Humphreys; Brenda M Booth Journal: Am J Drug Alcohol Abuse Date: 2010-05 Impact factor: 3.829
Authors: Roger D Weiss; Jennifer S Potter; Marc L Copersino; Kristi Prather; Petra Jacobs; Scott Provost; David Chim; Jeffrey Selzer; Walter Ling Journal: Am J Addict Date: 2010 Mar-Apr
Authors: Margaret L Griffin; Katherine A McDermott; R Kathryn McHugh; Garrett M Fitzmaurice; Robert N Jamison; Roger D Weiss Journal: Drug Alcohol Depend Date: 2016-04-25 Impact factor: 4.492
Authors: Katherine A McDermott; Margaret L Griffin; Hilary S Connery; E Yvette Hilario; David A Fiellin; Garrett M Fitzmaurice; Roger D Weiss Journal: J Clin Psychiatry Date: 2015-02 Impact factor: 4.384